Breaking News

Amarantus, Catalent Ink cGMP Mfg. Pact

Catalent to provide biomanufacturing activities for MANF protein

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Amarantus BioScience has entered a manufacturing agreement with Catalent Pharma Solutions for clinical-grade production of MANF (mesencephalic-astrocyte-derived neurotrophic factor). Catalent will provide all cell line engineering, process development and cGMP biomanufacturing activities for the development of a high performance cell line expressing MANF protein that will then be advanced into scale up for cGMP production.   Catalent will use its GPEx technology, designed to create high-expressi...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters